You are here : Home / All Sectors / Healthcare / Pharmaceuticals & Drugs / AUROBINDO PHARMA

AUROBINDO PHARMA
Intrinsic Value | Fundamental Analysis

Returns | 1W : -2.9% , 1M : -2.9%,1Y : -12.9%
www.aurobindo.com
BOM : 524804     NSE : AUROPHARMA    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued]
Debt : Average
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward
Pledged Shares : None or < 25%
Oct 21,2021
Price(EOD): Rs. 705.40
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Affiliate Link.
Stock Market Investing Simplified- The best Video Course by Smart-Investing.in

Check out Industry Peers

Peers & Returns1W1M1Y
AUROBINDO PHARMA -2.9% -2.9% -12.9%
SUN PHARMACEUTICAL INDUSTRIES -2.8% 7% 67.4%
DIVIS LABORATORIES -3.4% 0.2% 58.9%
DR REDDYS LABORATORIES -6.3% -4.3% -6.4%
CIPLA -0% -4.7% 15.7%
GLAND PHARMA -4.3% -6.3% NA
PIRAMAL ENTERPRISES -5.4% 2.7% 106.2%
CADILA HEALTHCARE -6.3% -7.3% 20.1%
TORRENT PHARMACEUTICALS -3.9% -1.2% 8.6%


FUNDAMENTAL ANALYSIS OF AUROBINDO PHARMA

 
Fundamentals Score
[ Q(TTM): Jun2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]
Show Me the Stocks with Fundamentals better than AUROBINDO PHARMA Plus/Pro


VALUATION OF AUROBINDO PHARMA

 
Valuation Score
[As on : Oct 21,2021 ]

Ratio Consolidated
P/E
P/B
P/S
7.75
P/E Calculated based on EPS of 91.05
[ Mar2021 - Consolidated Results ]

1.88
P/B Calculated based on Book Value of 374.29
[ Mar2021 - Consolidated Results ]

1.68
P/S Calculated based on Revenues of 24551.8 Cr
[ TTM - Consolidated Results ]

Show Me the Stocks with Valuation better than AUROBINDO PHARMA Plus/Pro


FAIR VALUE OF AUROBINDO PHARMA

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-19%
-21%
-3%

SHARE PRICE MOMENTUM OF AUROBINDO PHARMA

DEBT

Year Debt/Equity ratio
Standalone Consolidated
2021
2020
2019
Avg_3yrs
0.25
0.29
0.4
0.31
0.23
0.33
0.5
0.35
[Last Annual Data : Mar2021]

PLEDGED SHARES

Pledged Shares
22.98 %
As on : Sep2021

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad

QTRLY RESULTS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-4.99%
-5.12%
-3.98%
-3.78%
-3.76%
-3.82%
-6.35%
-2.04%
QtrlyTrend
-8
Latest Qtr: Jun2021

AUROBINDO PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE LARGECAP -1.2% 3.5% 56.9%
S&P BSE ENHANCED VALUE -1.2% 12.2% 131%
S&P BSE 100 LARGECAP TMC -1.2% 3.3% 57.6%
S&P BSE CARBONEX -1.3% 3.9% 58%
S&P BSE 100 -1.3% 3.4% 57.9%
S&P BSE LARGE MIDCAP -1.5% 3.6% 59.8%
S&P BSE 200 -1.5% 3.6% 60.9%
S&P BSE 250 LARGEMIDCAP -1.6% 3.6% 61.4%
S&P BSE 500 -1.8% 3.7% 63.3%
S&P BSE ALLCAP -1.9% 3.7% 64.4%
S&P BSE DIVIDEND STABILITY -2.6% 8.4% 67%
S&P BSE HEALTHCARE -3.7% -3.1% 29.7%
S&P BSE SENSEX NEXT 50 -3.8% 2.8% 67.8%
NSE Indices1W1M1Y
NIFTY LARGE MIDCAP 250 -1.1% 5.6% 70%
NIFTY500 MULTICAP 50:25:25 -1.2% 5.4% NA
NIFTY 100 -1.3% 3.1% 57.1%
NIFTY 200 -1.6% 3.6% 60.7%
NIFTY 500 -1.8% 3.6% 63%
NIFTY 100 EQUAL WEIGHT -2.4% 2.6% 68.9%
NIFTY GROWTH SECTOR 15 -2.9% -0.4% 42.8%
NSE QUALITY 30 -3.1% -1.3% 46.2%
NIFTY HEALTHCARE -3.4% -2% NA
NIFTY NEXT 50 -3.6% 0.7% 60.9%
NIFTY PHARMA -3.8% -0.8% 21.8%

You may also like the below Video Courses


FAQ [Frequently Asked Questions]


Is AUROBINDO PHARMA good for long term investment?

As on 21-Oct-2021, the Fundamentals of AUROBINDO PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AUROBINDO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is AUROBINDO PHARMA UnderValued or OverValued?

As on 21-Oct-2021, AUROBINDO PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!

What is the Intrinsic Value of AUROBINDO PHARMA ?

As on 21-Oct-2021, the Intrinsic Value of AUROBINDO PHARMA is Rs. 875.31 determined based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 875.31
Fair Value [Median EV / Sales Model] : Rs. 897.75
Fair Value [Median Price / Sales Model] : Rs. 723.96
Median Fair Value of AUROBINDO PHARMA : Rs. 875.31

Is AUROBINDO PHARMA trading at a Premium or Discount?

As on 21-Oct-2021, AUROBINDO PHARMA is trading at a Discount of -19% based on the estimates of Median Intrinsic Value!

What is the Financial Performance of Industry Peers of AUROBINDO PHARMA ?

Check out Annual Financials of Industry Peers
Share Price & Financials of SUN PHARMACEUTICAL INDUSTRIES LTD | BOM: 524715 | NSE: SUNPHARMA
Share Price & Financials of DIVIS LABORATORIES LTD | BOM: 532488 | NSE: DIVISLAB
Share Price & Financials of DR REDDYS LABORATORIES LTD | BOM: 500124 | NSE: DRREDDY
Share Price & Financials of CIPLA LTD | BOM: 500087 | NSE: CIPLA
Share Price & Financials of GLAND PHARMA LTD | BOM: 543245 | NSE: GLAND
Check out Quarterly Results of Industry Peers
Quarterly Results of SUN PHARMACEUTICAL INDUSTRIES LTD
Quarterly Results of DIVIS LABORATORIES LTD
Quarterly Results of DR REDDYS LABORATORIES LTD
Quarterly Results of CIPLA LTD
Quarterly Results of GLAND PHARMA LTD

What are the Frequent Comparisons in this Industry?

Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
Browse Market Cap of Industry Peers
Market Cap of SUN PHARMACEUTICAL INDUSTRIES LTD
Market Cap of DIVIS LABORATORIES LTD
Market Cap of DR REDDYS LABORATORIES LTD
Market Cap of CIPLA LTD
Market Cap of GLAND PHARMA LTD

Disclosure

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].


All Stocks : A - Z

ALL   A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z